Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Pharmacological therapies for the treatment of opioid-induced constipation

A study in October's issue of the American Journal of Gastroenterology evaluates the efficacy of pharmacological therapies for the treatment of opioid-induced constipation.

News image

There has been no definitive synthesis of the evidence for any benefit of available pharmacological therapies in opioid-induced constipation.

Dr Alexander Ford and colleagues from the United Kingdom conducted a systematic review and meta-analysis to address this deficit.

The team searched MEDLINE, EMBASE, EMBASE Classic, and the Cochrane central register of controlled trials through to 2012 to identify placebo-controlled trials of μ-opioid receptor antagonists, prucalopride, lubiprostone, and linaclotide in the treatment of adults with opioid-induced constipation.

No minimum duration of therapy was required.

Trials had to report a dichotomous assessment of overall response to therapy, and data were pooled using a random effects model.

The research team identified 14 eligible randomized controlled trials of μ-opioid receptor antagonists, containing 4,101 patients.

These were superior to placebo for the treatment of opioid-induced constipation.

The researchers noted that methylnaltrexone, naloxone, and alvimopan were all superior to placebo.

The team found that total numbers of adverse events, diarrhea, and abdominal pain were significantly commoner when data from all RCTs were pooled.

Reversal of analgesia did not occur more frequently with active therapy.

Only one trial of prucalopride was identified, with a nonsignificant trend toward higher responder rates with active therapy.

The research team found that 2 randomized controlled trials of lubiprostone, with significantly higher responder rates with lubiprostone in both, but reporting of data precluded meta-analysis.

Dr Ford's team commented, "μ-Opioid receptor antagonists are safe and effective for the treatment of opioid-induced constipation."

"More data are required before the role of prucalopride or lubiprostone in the treatment of opioid-induced constipation are clear."

Am J Gastroenterol 2013; 108: 15661574
17 October 2013

Go to top of page Email this page Email this page to a colleague

 28 May 2015

Advanced search
 28 May 2015 
Bleeding and colorectal endoscopic submucosal dissection
 28 May 2015 
Excercise and IBD
 28 May 2015 
Probiotics and Crohn's disease
 27 May 2015 
Management of constipation and IBS
 27 May 2015 
Vegetables and fruit and IBD
 27 May 2015 
Radiofrequency ablation for treatment of GERD
 26 May 2015 
Calcium channel blockers and GI bleeds
 26 May 2015 

Risk factors for celiac disease

 26 May 2015 
Antimicrobials for intraabdominal infection
 25 May 2015 
Risk of GI bleeds with NSAIDs
 25 May 2015 
Colorectal cancer screening
 25 May 2015 
Saccharomyces boulardii and H. pylori
 22 May 2015 
Treatment with anti-integrin antibodies in IBD
 22 May 2015 
Care of patients with GERD
 22 May 2015 
Colonoscopy screening for colorectal cancer
 21 May 2015 
Imaging for hepatocellular carcinoma
 21 May 2015 
Lymphoma in IBD
 21 May 2015 
Serrated polyps and colorectal cancer
 20 May 2015 
Refractory metastatic colorectal cancer
 20 May 2015 
Surveillance in long-segment Barrett's
 20 May 2015 
Pancreatic neuroendocrine tumors
 19 May 2015 
PPIs and cryptogenic liver abscess
 19 May 2015 
Anti-integrin antibodies in IBD
 19 May 2015 
Metabolic syndrome and Barrett's
 18 May 2015 
HLA haplotypes and primary sclerosing cholangitis
 18 May 2015 
Safety of PPI
 18 May 2015 
ESPGHAN celiac guidelines
 15 May 2015 
Management of nonhospitalized ulcerative colitis
 15 May 2015 
Diabetes and infections in IBD with immunomodulation
 15 May 2015 
Microscopic colitis risk with PPIs/NSAIDs
 14 May 2015 
Diagnosis of spontaneous bacterial peritonitis
 14 May 2015 
Mortality in US patients with cirrhosis
 14 May 2015 
Radiation exposure during ERCP
 13 May 2015 
Hypnotherapy in IBS/IBD
 13 May 2015 
Predictors of IBD
 13 May 2015 
Psychological distress and liver disease mortality
 12 May 2015 
Bleeding in NSAID users with H.pylori
 12 May 2015 
Capsule colonoscopy detects colorectal polyps
 12 May 2015 
Anti-TNF biologics in acute severe ulcerative colitis
 11 May 2015 
Management of Barrett's esophagus
 11 May 2015 
Marker to detect recurrence of Crohn's
 11 May 2015 
Thalidomide for IBD
 08 May 2015 
Surveillance colonoscopy in colorectal cancer
 08 May 2015 
HCV treatment with compensated cirrhosis
 08 May 2015 
Medical management of Crohn's
 07 May 2015 
Surgical complications in ulcerative colitis
 07 May 2015 
Combination therapy for noncirrhostic patients
 07 May 2015 
Anxiety and new-onset dyspepsia
 06 May 2015 
PPIs and spontaneous bacterial peritonitis
 06 May 2015 
Infant feeding and celiac disease
 06 May 2015 
Preventing recurrent C. diff infection
 05 May 2015 
Fatigue in primary sclerosing cholangitis
 05 May 2015 
Annual CT scans after esophagectomy for cancer
 05 May 2015 
Prevalence of eosinophilic esophagitis
 04 May 2015 
Stress resilience and peptic ulcer disease
 04 May 2015 
Endoscope storage and microbial colonization
 04 May 2015 
Menarche and NAFLD
 01 May 2015 
Sleep and physical activity measured in Crohn's
 01 May 2015 
NAFLD progression from steatosis to fibrosing-steatohepatitis
 01 May 2015 
Dietary supplement hepatotoxicity

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us